ABSTRACT
Data from two recent major trials suggest that several changes in clinical practice would benefit hepatitis C patients, including viral genotyping to more accurately determine the duration of therapy, and timely RNA measurement to predict treatment response. Although the combination of interferon alfa-2b and ribavirin therapy has proved superior to interferon alone, the success of interferon-based therapies in eradicating hepatitis C is limited, and the quest for new strategies and treatments continues.
Footnotes
↵* Dr. McHutchison receives grant or research support from the Schering-Plough, Amgen, Roche, and Gilead companies, has served as a consultant for Schering-Plough and Roche, and has served on speakers’ bureaus for Schering-Plough, Roche, and Amgen . Dr. Younossi receives research support from Schering-Plough, Roche, and Interferon Sciences.
- Copyright © 2000 The Cleveland Clinic Foundation. All Rights Reserved.